Return to Home Page Tables and Charts Glossary of Terms Resources
Executive Summary Methodology Profile of Respondents Plan Design Features Cost Sharing Highlights Pharmacy Reimbursement Highlights Drug Cost Highlights Utilization Management Highlights
 
FDA Uses Many Tools to Monitor Drugs
 
The U.S. Food and Drug Administration (FDA) has multiple initiatives to improve prescription drug safety.

Monitoring and Management
MedWatch is the FDA’s Adverse Event Reporting Program. Drug manufacturers, health care professionals, and consumers submit reports of adverse events online at www.fda.gov/medwatch/how.htm.

The FDA monitors and investigates these reports, issues safety alerts, and requires labeling changes or market withdrawal of a drug if necessary. The FDA is upgrading the reporting system so reviewers can identify and track safety issues more efficiently. The agency also is exploring ways to link private and public sector post-marketing monitoring systems to improve data collection and risk identification.

A Drug Safety Oversight Board (DSB) was created in 2005 to provide advice on managing drug safety issues. It also manages the flow of emerging safety information to health care professionals and patients.

To date, the board has met 11 times to discuss complex drug safety issues, including actions on the Fentanyl® transdermal patch and Palladone®. In 2005 and 2006, the DSB published 80 Healthcare Professional Sheets, 79 Patient Information Sheets, and 47 Public Health Advisories.

Communication Tools
With the benefit of advisory committee expertise, the FDA will be evaluating its current communication tools. It will also be developing a comprehensive risk-communication strategic plan.

Current resources for FDA information on drug safety issues include:

» MedWatch Alerts – Email notification of all safety alerts for drugs, biologics, dietary supplements, and devices, plus monthly labeling changes. Subscribe for free at www.fda.gov/medwatch.

» Drug Safety Podcasts – New from the FDA’s Center for Drug Evaluation and Research (CDER), the podcasts are produced in conjunction with the release of Public Health Advisories. They are available at www.fda.gov/cder/drug/podcast/default.htm

» News from CDER at www.fda.gov/cder/index.html, contains links to information on the FDA’s drug safety initiatives.

» DailyMed Web site – Developed in collaboration with the National Library of Medicine, this new standardized electronic drug-label library allows physicians and patients to access up-to-date information at http://dailymed.nlm.nih.gov.



Proactive Management for Specialty Pharmacy

Medicare Part D Strategies to Change Over Time

Lowering Copays to Increase Treatment Adherence

Changing the Drug Reimbursement Landscape

Decreased Copays Encourage Voluntary Pill Splitting

Strengthening Prescription Drug Safety

 

 

 

 

 

 

 

 

 

 

 

 

 

 

© 2007 Pharmacy Benefit Management Institute | 8679 E. San Alberto Dr., Ste. 101 | Scottsdale, AZ 85258-4368 | 480.730.0814